

John A Radford

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1388335/john-a-radford-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

260
papers

16,636
citations

68
h-index

124
g-index

275
ext. papers

19,183
ext. citations

6.2
avg, IF

5.85
L-index

#	Paper	IF	Citations
260	The perspectives of survivors of Hodgkin lymphoma on lung cancer screening: A qualitative study. <i>Health Expectations</i> , 2021 ,	3.7	3
259	Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project. <i>Blood</i> , 2021 , 138, 213-220	2.2	7
258	Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. <i>Lancet Oncology, The</i> , 2021 , 22, 790-800	21.7	56
257	Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. <i>Lancet Haematology,the</i> , 2021 , 8, e410-e421	14.6	20
256	Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trial. <i>British Journal of Haematology</i> , 2021 , 192, 1015-1019	4.5	2
255	FDG-PET/CT after two cycles of R-CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome - final result of a UK National Cancer Research Institute prospective study. <i>British Journal of Haematology</i> , 2021 , 192, 504-513	4.5	11
254	Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response-adapted design in the first-line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY). <i>British Journal of Haematology</i> , 2021 , 193, 63-71	4.5	5
253	Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. <i>Blood</i> , 2021 , 137, 2634-2645	2.2	44
252	Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma. <i>Blood</i> , 2021 , 137, 637-645	2.2	31
251	Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high-risk patients from the ECHELON-1 study. <i>Hematological Oncology</i> , 2021 , 39, 185-195	1.3	3
250	Predicted Risks of Cardiovascular Disease Following Chemotherapy and Radiotherapy in the UK NCRI RAPID Trial of Positron Emission Tomography-Directed Therapy for Early-Stage Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3591-3601	2.2	1
249	Avelumab in relapsed/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial. <i>Blood Advances</i> , 2021 , 5, 3387-3396	7.8	4
248	ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project. <i>Blood Advances</i> , 2021 , 5, 640-648	7.8	6
247	Quantitative assessment of interim PET in Hodgkin lymphoma: An evaluation of the qPET method in adult patients in the RAPID trial. <i>PLoS ONE</i> , 2020 , 15, e0231027	3.7	5
246	Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis. <i>Leukemia and Lymphoma</i> , 2020 , 61, 950-954	1.9	6
245	R-GEM-Lenalidomide versus R-GEM-P as second-line treatment of diffuse large B-cell lymphoma: results of the UK NCRI phase II randomised LEGEND trial. <i>Annals of Hematology</i> , 2020 , 99, 105-112	3	3
244	Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. <i>Lancet Oncology, The</i> , 2020 , 21, 1433-1442	21.7	114

243	Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. <i>Blood</i> , 2020 , 135, 735-742	2.2	54
242	Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I/IIA Hodgkin lymphoma. <i>Blood Advances</i> , 2020 , 4, 203-206	7.8	10
241	Reply to H.J.A. Adams et al and C. Kobe et al. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3325-3326	2.2	
240	Positron Emission Tomography Score Has Greater Prognostic Significance Than Pretreatment Risk Stratification in Early-Stage Hodgkin Lymphoma in the UK RAPID Study. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1732-1741	2.2	26
239	Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. <i>Blood</i> , 2019 , 134, 1144-1153	2.2	148
238	Real-World Data of High-Grade Lymphoma Patients Treated with CD19 CAR-T in England. <i>Blood</i> , 2019 , 134, 767-767	2.2	17
237	Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma. <i>Blood</i> , 2019 , 134, 123-123	2.2	24
236	Interim Futility Analysis of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2019 , 134, 757-757	2.2	7
235	A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2019 , 25, 6986-6994	12.9	49
234	Toxic epidermal necrolysis (TEN) associated with the use of nivolumab (PD-1 inhibitor) for lymphoma. <i>JAAD Case Reports</i> , 2018 , 4, 229-231	1.4	25
233	Brentuximab Vedotin for Stage III or IV Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2018 , 378, 1560-1561	59.2	9
232	CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial. <i>Lancet Haematology</i> , 2018 , 5, e190-e200	14.6	33
231	Early-stage Hodgkin lymphoma in the modern era: simulation modelling to delineate long-term patient outcomes. <i>British Journal of Haematology</i> , 2018 , 182, 212-221	4.5	7
230	Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2018 , 182, 583-586	4.5	35
229	A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy. <i>Haematologica</i> , 2018 , 103, 1351-1358	6.6	32
228	The iR2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) Is Active with a Manageable Safety Profile in Patients with Relapsed/Refractory Non-Germinal Center-like Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2018 , 132, 402-402	2.2	2
227	A Comparison of Prognostic Indices in Diffuse Large B-Cell Lymphoma within the UK NCRI R-CHOP 14 Versus 21 Phase III Trial. <i>Blood</i> , 2018 , 132, 2956-2956	2.2	1
226	Older Patients (pts) with Previously Untreated Classical Hodgkin Lymphoma (cHL): A Detailed Analysis from the Phase 3 ECHELON-1 Study. <i>Blood</i> , 2018 , 132, 1618-1618	2.2	7

225	Updated Report on Identification of Molecular Predictors of Tazemetostat Response in an Ongoing NHL Phase 2 Study. <i>Blood</i> , 2018 , 132, 4097-4097	2.2	3
224	Interim Results from the First-in-Human Clinical Trial of Adct-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2018 , 132, 398-398	2.2	8
223	Safety and Efficacy of Adct-402 (Loncastuximab Tesirine), a Novel Antibody Drug Conjugate, in Relapsed/Refractory Follicular Lymphoma and Mantle Cell Lymphoma: Interim Results from the Phase 1 First-in-Human Study. <i>Blood</i> , 2018 , 132, 2874-2874	2.2	8
222	Phase 1 Study of Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Classical Hodgkin Lymphoma. <i>Blood</i> , 2018 , 132, 928-928	2.2	31
221	A phase 1, open-label, multicenter, non-randomized study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of AZD4573, a potent and selective CDK9 inhibitor, in subjects with relapsed or refractory hematological malignancies.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS7588-TPS7588	2.2	2
220	Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2018 , 378, 331-344	59.2	378
219	Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma. <i>British Journal of Haematology</i> , 2018 , 180, 224-235	4.5	8
218	Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital. <i>Leukemia and Lymphoma</i> , 2018 , 59, 1586-1595	1.9	7
217	Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2395-2404	2.2	100
216	Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2405-2412	2.2	55
215	Interim Update from a Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018 , 18, S278-S279	2	4
214	Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2018 , 19, 1530-1542	21.7	59
213	Letter comments on a published article in the New England Journal of Medicine. <i>European Journal of Cancer</i> , 2018 , 104, 250-251	7.5	
212	Treatment pathways and resource use associated with recurrent Hodgkin lymphoma after autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2017 , 52, 452-454	4.4	3
211	Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study. <i>Journal of Clinical Oncology</i> , 2017 , 35, 544-551	2.2	99
210	Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial. <i>Annals of Oncology</i> , 2017 , 28, 2511-2516	10.3	36
209	Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2125-2132	2.2	641
208	Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting. <i>British Journal of Haematology</i> , 2017 , 179, 471-479	4.5	13

207	019 Chemotherapy-induced cardiotoxicity: could a translational cardiac MRI model help identify patients at risk?. <i>Heart</i> , 2017 , 103, A16-A17	5.1	
206	Bendamustine can be a bridge to allogeneic transplantation in relapsed Hodgkin lymphoma refractory to brentuximab vedotin. <i>British Journal of Haematology</i> , 2017 , 179, 841-843	4.5	7
205	Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study. <i>Bone Marrow Transplantation</i> , 2017 , 52, 216-221	4.4	77
204	European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma. <i>Haematologica</i> , 2016 , 101, e407-e410	6.6	28
203	Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2016 , 374, 2419-29	59.2	428
202	Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial. <i>Lancet Oncology</i> , 2016 , 17, 319-331	21.7	103
201	The European Hematology Association Roadmap for European Hematology Research: a consensus document. <i>Haematologica</i> , 2016 , 101, 115-208	6.6	46
200	Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. <i>Bone Marrow Transplantation</i> , 2016 , 51, 51-7	4.4	149
199	Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Primary End Point Analysis of the Phase 2 Keynote-087 Study. <i>Blood</i> , 2016 , 128, 1107-1107	2.2	32
198	The Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma As Determined By Whole Genome Expression Profiling on Paraffin Embedded Tissue Is Independently Associated with Reduced Overall and Progression Free Survival in the Rituximab Era: Results from the UK NCRI R-CHOP 14 v 21 Phase III Trial. <i>Blood</i> , 2016 , 128, 1746-1746	2.2	5
197	Pseudo-Progression Among Patients with Follicular Lymphoma Treated with Ibrutinib in the Phase 2 DAWN Study. <i>Blood</i> , 2016 , 128, 2980-2980	2.2	2
196	Polatuzumab Vedotin Combined with Bendamustine (B) and Rituximab (R) or Obinutuzumab (G) in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib/II Dose-Escalation Study. <i>Blood</i> , 2016 , 128, 4194-4194	2.2	1
195	Pembrolizumab for relapsed/refractory classical Hodgkin lymphoma (R/R cHL): phase 2 KEYNOTE-087 study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 7555-7555	2.2	11
194	Phase 2 multi-center study of tazemetostat (EPZ-6438), an inhibitor of enhancer of zeste-homolog 2 (EZH2), in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL).. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS7582-TPS7582	2.2	11
193	Outcomes Following Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma Patients at Risk of Bleeding Events Because of Multiple Comorbidities or Treatment: A Post-Hoc Subgroup Analysis of the SPRINT (MCL-002) Trial. <i>Blood</i> , 2016 , 128, 2978-2978	2.2	
192	An Association of Cancer Physicians' strategy for improving services and outcomes for cancer patients. <i>Ecancermedalscience</i> , 2016 , 10, 608	2.7	1
191	Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group study. <i>British Journal of Haematology</i> , 2016 , 173, 274-82	4.5	11
190	Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma: An updated review of published data from the named patient program. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 104, 65-70	7	15

189	PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study. <i>Blood</i> , 2016 , 127, 1531-8	2.2	105
188	Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2016 , 175, 860-867	4.5	18
187	Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial. <i>British Journal of Haematology</i> , 2016 , 175, 668-672	4.5	29
186	A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer. <i>Annals of Oncology</i> , 2015 , 26, 1923-1929	10.3	54
185	Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. <i>New England Journal of Medicine</i> , 2015 , 372, 1598-607	59.2	437
184	A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015 , 56, 2863-9	1.9	26
183	Experience of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma and relapsed/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: Review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 95, 359-69	7	24
182	PET-Directed Therapy for Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2015 , 373, 392	59.2	15
181	XVI. Early stage Hodgkin lymphoma. <i>Hematological Oncology</i> , 2015 , 33 Suppl 1, 84-6	1.3	1
180	A phase II trial of AZD1152 in relapsed/refractory diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2015 , 170, 886-90	4.5	25
179	Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. <i>Blood</i> , 2015 , 126, 739-45	2.2	268
178	Treatment of Hodgkin lymphoma in older patients. <i>Blood</i> , 2015 , 126, 2768-9	2.2	0
177	QuantiGene Plex Represents a Promising Diagnostic Tool for Cell-of-Origin Subtyping of Diffuse Large B-Cell Lymphoma. <i>Journal of Molecular Diagnostics</i> , 2015 , 17, 402-11	5.1	9
176	R-CHOP in Primary Mediastinal B-Cell Lymphoma (PMBL): Results from the UK NCRI R-CHOP 14 v 21 Trial. <i>Blood</i> , 2015 , 126, 2689-2689	2.2	2
175	Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Relapsing after Autologous Stem Cell Transplantation (ASCT): An Analysis of Patients Included in the Coral Study. <i>Blood</i> , 2015 , 126, 517-517 ²	2.2	1
174	Outcome of Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: Subgroup Analysis from the UK NCRI R-CHOP 14 Vs 21 Trial. <i>Blood</i> , 2015 , 126, 1516-1516	2.2	
173	Improved Survival in Peripheral T-Cell Lymphoma (PTCL) Following Complete Response to First-Line Chemotherapy: 10 Year Experience at the Royal Marsden and the Christie Hospitals 2002-2012. <i>Blood</i> , 2015 , 126, 1499-1499	2.2	
172	An integrated characterization of serological, pathological, and functional events in doxorubicin-induced cardiotoxicity. <i>Toxicological Sciences</i> , 2014 , 140, 3-15	4.4	37

171	Clinical features, management and prognosis of multifocal primary bone lymphoma: a retrospective study of the international extranodal lymphoma study group (the IELSG 14 study). <i>British Journal of Haematology</i> , 2014 , 164, 834-40	4.5	39
170	The clinical features, management and prognostic effects of pathological fractures in a multicenter series of 373 patients with diffuse large B-cell lymphoma of the bone. <i>Annals of Oncology</i> , 2014 , 25, 176-81	10.3	14
169	The clinical features, management and prognosis of primary and secondary indolent lymphoma of the bone: a retrospective study of the International Extranodal Lymphoma Study Group (IELSG #14 study). <i>Leukemia and Lymphoma</i> , 2014 , 55, 1796-9	1.9	11
168	De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial. <i>Journal of Clinical Oncology</i> , 2014 , 32, 282-7	2.2	64
167	Fractionated α -ibrutumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma: an international phase II study in patients requiring treatment according to GELF/BNLI criteria. <i>Journal of Clinical Oncology</i> , 2014 , 32, 212-8	2.2	50
166	Current knowledge and future research directions in treatment-related second primary malignancies. <i>European Journal of Cancer, Supplement</i> , 2014 , 12, 5-17	1.6	39
165	Clinical features, management, and prognosis of an international series of 161 patients with limited-stage diffuse large B-cell lymphoma of the bone (the IELSG-14 study). <i>Oncologist</i> , 2014 , 19, 291-8	5.7	46
164	Risk of premature menopause after treatment for Hodgkin's lymphoma. <i>Journal of the National Cancer Institute</i> , 2014 , 106,	9.7	37
163	Single-Agent Ibrutinib Demonstrates Safety and Durability of Response at 2 Years Follow-up in Patients with Relapsed or Refractory Mantle Cell Lymphoma: Updated Results of an International, Multicenter, Open-Label Phase 2 Study. <i>Blood</i> , 2014 , 124, 4453-4453	2.2	11
162	Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The Orchard Study (OMB110928). <i>Blood</i> , 2014 , 124, 630-630	2.2	16
161	Starlyte phase II study of coltuximab ravtansine (CoR, SAR3419) single agent: Clinical activity and safety in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL; NCT01472887).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8506-8506	2.2	9
160	Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab (R-InO) versus chemotherapy for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (B-NHL).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8529-8529	2.2	4
159	Phase 3 study of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as front-line treatment for advanced classical Hodgkin lymphoma (HL): Echelon-1 study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS8613-TPS8613	2.2	3
158	A Phase 2 Trial of AZD1152 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2014 , 124, 4481-4481	2.2	
157	Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. <i>New England Journal of Medicine</i> , 2013 , 369, 507-16	59.2	1139
156	Inhibitor kinazy Brutona u chorych z nawrotowym lub opornym na leczenie chłoniakiem z komórek płaszczą Wyniki międzynarodowego, wieloośrodkowego, badania II fazy z ibrutynibem (PCI-32765) EHA Encore. <i>Acta Haematologica Polonica</i> , 2013 , 44, 314-318	0.4	1
155	Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. <i>Lancet, The</i> , 2013 , 381, 1817-26	40	354
154	Breast cancer risk following Hodgkin lymphoma radiotherapy in relation to menstrual and reproductive factors. <i>British Journal of Cancer</i> , 2013 , 108, 2399-406	8.7	39

153	A statistical framework for analyzing hypothesized interactions between cells imaged using multispectral microscopy and multiple immunohistochemical markers. <i>Journal of Pathology Informatics</i> , 2013 , 4, S4	4.4	9
152	PLK1 and YY1 interaction in follicular lymphoma is associated with unfavourable outcome. <i>Journal of Clinical Pathology</i> , 2013 , 66, 764-7	3.9	14
151	A randomized study of interferon β versus no treatment as consolidation after high dose therapy and autologous stem cell transplantation for patients with relapsed lymphoma. <i>Oncologist</i> , 2013 , 18, 1189	5.7	5
150	⁹⁰ Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-Line Indolent trial. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1977-83	2.2	154
149	A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2013 , 163, 334-42	4.5	33
148	A study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicity. <i>British Journal of Cancer</i> , 2013 , 109, 2560-5	3.7	6
147	Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000). <i>Blood</i> , 2013 , 122, 1137-43	2.2	95
146	Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center. <i>Haematologica</i> , 2013 , 98, 611-4	6.6	81
145	Diffuse Large B-Cell Lymphoma (DLBCL) Patients Failing Second-Line R-DHAP Or R-ICE Chemotherapy Included In The Coral Study. <i>Blood</i> , 2013 , 122, 764-764	2.2	7
144	Obinutuzumab (GA101) Plus CHOP Or FC In Relapsed/Refractory Follicular Lymphoma: Final Data From The Maintenance Phase Of The Phase 1b GAUDI Study (BO21000). <i>Blood</i> , 2013 , 122, 1814-1814	2.2	
143	Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. <i>Blood</i> , 2012 , 119, 3698-704	2.2	118
142	Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4462-9	2.2	194
141	Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences. <i>British Journal of Haematology</i> , 2012 , 159, 154-63	4.5	74
140	Microarray gene expression analysis of fixed archival tissue permits molecular classification and identification of potential therapeutic targets in diffuse large B-cell lymphoma. <i>Journal of Molecular Diagnostics</i> , 2012 , 14, 223-32	5.1	22
139	Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1647-55	2.2	140
138	Burkitt's lymphoma of an ileal pouch following restorative proctocolectomy. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, E1596-7	4.5	6
137	Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin's lymphoma in England and Wales: a National Cohort Study. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2745-52	2.2	100
136	Treatment for early-stage hodgkin lymphoma: has radiotherapy had its day?. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3783-5	2.2	7

135	A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2011 , 152, 570-8	4.5	34
134	How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?. <i>British Journal of Pharmacology</i> , 2011 , 163, 675-93	8.6	247
133	Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma. <i>British Journal of Cancer</i> , 2011 , 104, 719-25	8.7	36
132	Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4096-104	2.2	127
131	YY1 expression predicts favourable outcome in follicular lymphoma. <i>Journal of Clinical Pathology</i> , 2011 , 64, 125-9	3.9	25
130	Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG-PET data for clinical trials in lymphoma. <i>Annals of Oncology</i> , 2011 , 22, 739-745	10.3	53
129	Obinutuzumab (GA101) in Combination with FC or CHOP in Patients with Relapsed or Refractory Follicular Lymphoma: Final Results of the Phase I GAUDI Study (BO21000). <i>Blood</i> , 2011 , 118, 270-270	2.2	7
128	Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin + Rituximab Followed by Stem Cell Transplantation in Relapsed/Refractory DLBCL Patients: Safety and Efficacy. <i>Blood</i> , 2011 , 118, 2718-2718	2.2	2
127	Pharmacokinetics of Obinutuzumab (GA101) in Patients with CD20+ Relapsed/Refractory Malignant Disease Receiving Concomitant Chemotherapy (Phase Ib Study BO21000). <i>Blood</i> , 2011 , 118, 3704-3704	2.2	3
126	Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma. <i>British Journal of Haematology</i> , 2010 , 150, 565-73	4.5	62
125	Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2010 , 151, 346-53	4.5	57
124	A20 is targeted by promoter methylation, deletion and inactivating mutation in MALT lymphoma. <i>Leukemia</i> , 2010 , 24, 483-7	10.7	101
123	Initial dose intensity has limited impact on the outcome of ABVD chemotherapy for advanced Hodgkin lymphoma (HL): data from UKLG LY09 (ISRCTN97144519). <i>Annals of Oncology</i> , 2010 , 21, 568-573	10.3	11
122	Consolidation radiotherapy in patients with advanced Hodgkin's lymphoma: survival data from the UKLG LY09 randomized controlled trial (ISRCTN97144519). <i>Journal of Clinical Oncology</i> , 2010 , 28, 3352-9	2.2	61
121	Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010 , 37, 1824-33	8.8	235
120	Ofatumumab Monotherapy for Treatment of Patients with Relapsed/Progressive Diffuse Large B-Cell Lymphoma: Results From a Multicenter Phase II Study. <i>Blood</i> , 2010 , 116, 3955-3955	2.2	7
119	90Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission In Advanced-Stage Follicular Non-Hodgkin's Lymphoma: Updated Results After a Median Follow-up of 66.2 Months From the International, Randomized, Phase III First-Line Indolent Trial (FIT) In 414 Patients. <i>Blood</i> , 2010 , 116, 594-594	2.2	8
118	Trabectedin (Tr) in the treatment of advanced uterine leiomyosarcomas (U-LMS): Results of a pooled analysis of five single-agent phase II studies using the recommended dose.. <i>Journal of Clinical Oncology</i> , 2010 , 28, 10028-10028	2.2	11

117	Methods comparison for high-resolution transcriptional analysis of archival material on Affymetrix Plus 2.0 and Exon 1.0 microarrays. <i>BioTechniques</i> , 2009 , 47, 587-96	2.5	41
116	The UK national breast cancer screening programme for survivors of Hodgkin lymphoma detects breast cancer at an early stage. <i>British Journal of Cancer</i> , 2009 , 101, 582-8	8.7	35
115	A20 deletion is associated with copy number gain at the TNFA/B/C locus and occurs preferentially in translocation-negative MALT lymphoma of the ocular adnexa and salivary glands. <i>Journal of Pathology</i> , 2009 , 217, 420-30	9.4	103
114	Acquisition of biologically relevant gene expression data by Affymetrix microarray analysis of archival formalin-fixed paraffin-embedded tumours. <i>British Journal of Cancer</i> , 2008 , 98, 1403-14	8.7	72
113	Patterns of mortality after prolonged follow-up of a randomised controlled trial using granulocyte colony-stimulating factor to maintain chemotherapy dose intensity in non-Hodgkin's lymphoma. <i>British Journal of Cancer</i> , 2008 , 99, 253-8	8.7	10
112	A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). <i>Blood</i> , 2008 , 112, 2248-60	2.2	165
111	Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy. <i>Annals of Oncology</i> , 2008 , 19, 835-46	10.3	71
110	Limited-stage disease: optimal use of chemotherapy and radiation treatment. <i>Hematology American Society of Hematology Education Program</i> , 2008 , 321-5	3.1	3
109	Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5156-64	2.2	378
108	Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group. <i>Annals of Oncology</i> , 2008 , 19, 233-41	10.3	144
107	First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. <i>Blood</i> , 2008 , 111, 5486-95	2.2	223
106	Clinical quantitation of immune signature in follicular lymphoma by RT-PCR-based gene expression profiling. <i>Blood</i> , 2008 , 111, 4764-70	2.2	79
105	Extended Follow-up of the International Randomized Phase 3 First-Line Indolent Trial (FIT) Shows Durable Benefit of 90 Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission in Advanced Stage Follicular Non-Hodgkin's Lymphoma. <i>Blood</i> , 2008 , 112, 2002-2002	2.2	2
104	Consolidation Radiotherapy Is Associated with Improved Outcomes after Chemotherapy for Advanced Hodgkin Lymphoma: Analysis of Results from the UKLG LY09 Trial (ISRCTN97144519). <i>Blood</i> , 2008 , 112, 368-368	2.2	2
103	Results of the 2nd Planned Interim Analysis of the RAPID Trial (involved field radiotherapy versus no further treatment) in Patients with Clinical Stages 1A and 2A Hodgkin Lymphoma and a Negative FDG-PET Scan after 3 Cycles ABVD. <i>Blood</i> , 2008 , 112, 369-369	2.2	14
102	A Blood Borne Biomarker of Cell Death (nucleosomal DNA) Is An Early Predictor of End of Treatment Response to Chemotherapy in Lymphoma. <i>Blood</i> , 2008 , 112, 4828-4828	2.2	
101	Quality Control of PET Imaging in a Multicentre Phase III Trial (RAPID) Involving Randomisation of Patients with Stages IA and IIA Hodgkin Lymphoma Who Are PET Negative After 3 Cycles of ABVD Chemotherapy. <i>Blood</i> , 2008 , 112, 1449-1449	2.2	
100	Ovarian Tissue Banking. <i>Journal of Mammalian Ova Research</i> , 2007 , 24, 8-13		1

99	Financial incentives and GPs: What about the impact on patient health?. <i>BMJ, The</i> , 2007 , 335, 60	5.9	1
98	Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3144-50	2.2	209
97	Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. <i>Journal of the National Cancer Institute</i> , 2007 , 99, 206-14	9.7	353
96	Phase I evaluation of a fully human anti-alpha v integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , 2007 , 13, 2128-35	12.9	124
95	Clinical quantitation of diagnostic and predictive gene expression levels in follicular and diffuse large B-cell lymphoma by RT-PCR gene expression profiling. <i>Blood</i> , 2007 , 109, 3922-8	2.2	60
94	90Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission in Advanced Stage Follicular Non-Hodgkin's Lymphoma: First Results of the International Randomized Phase 3 First-Line Indolent Trial (FIT) in 414 Patients.. <i>Blood</i> , 2007 , 110, 643-643	2.2	19
93	Clinical Measurement of Prognostic Immune Signature in Follicular Lymphoma by RT-PCR Based Gene Expression Profiling and Immunohistochemistry Demonstrates Favourable T-Cell and Unfavorable Macrophage Infiltration.. <i>Blood</i> , 2007 , 110, 359-359	2.2	
92	Response evaluation in gastrointestinal stromal tumours treated with imatinib: misdiagnosis of disease progression on CT due to cystic change in liver metastases. <i>British Journal of Radiology</i> , 2006 , 79, e40-4	3.4	34
91	Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. <i>Annals of Oncology</i> , 2006 , 17, 1749-60	10.3	135
90	Sequential high dose chemotherapy as initial treatment for aggressive sub-types of non-Hodgkin lymphoma: results of the international randomized phase III trial (MISTRAL). <i>Annals of Oncology</i> , 2006 , 17, 1546-52	10.3	30
89	Bacteria-eradicating therapy for ocular adnexal MALT lymphoma: questions for an open international prospective trial. <i>Annals of Oncology</i> , 2006 , 17, 1721-2	10.3	13
88	Comparison of outcomes in studies of advanced Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3309; author reply 3309-10	2.2	
87	Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. <i>Journal of Clinical Oncology</i> , 2006 , 24, 2105-12	2.2	151
86	Chlamydia psittaci is variably associated with ocular adnexal MALT lymphoma in different geographical regions. <i>Journal of Pathology</i> , 2006 , 209, 344-51	9.4	196
85	Zanolimumab, a Fully Human Monoclonal Antibody: Preliminary Results of an Ongoing Clinical Trial in CD4+ Peripheral T-Cell Lymphomas (PTCL).. <i>Blood</i> , 2006 , 108, 2723-2723	2.2	1
84	YY1 Expression Predicts Survival in Follicular and Diffuse Large B-Cell Lymphoma.. <i>Blood</i> , 2006 , 108, 2033-2033		
83	Lung cancer after treatment for Hodgkin's lymphoma: a systematic review. <i>Lancet Oncology, The</i> , 2005 , 6, 773-9	21.7	71
82	Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. <i>Journal of Clinical Oncology</i> , 2005 , 23, 576-84	2.2	350

81	Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. <i>Blood</i> , 2005 , 105, 4576-82	2.2	138
80	Killing of non-Hodgkin lymphoma cells by autologous CD19 engineered T cells. <i>British Journal of Haematology</i> , 2005 , 129, 322-32	4.5	19
79	MALT lymphoma with t(14;18)(q32;q21)/IGH-MALT1 is characterized by strong cytoplasmic MALT1 and BCL10 expression. <i>Journal of Pathology</i> , 2005 , 205, 293-301	9.4	129
78	Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab. <i>Journal of Clinical Oncology</i> , 2005 , 23, 7985-93	2.2	90
77	Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). <i>Journal of Clinical Oncology</i> , 2005 , 23, 9208-18	2.2	115
76	Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , 2004 , 22, 1469-79	2.2	96
75	Ultrastructural preservation of ovarian cortical tissue cryopreserved in dimethylsulfoxide for subsequent transplantation into young female cancer patients. <i>Ultrastructural Pathology</i> , 2004 , 28, 239-45	1.3	33
74	Limited field radiotherapy for early stage, infra-diaphragmatic Hodgkin's lymphoma. <i>Clinical Oncology</i> , 2004 , 16, 53-7	2.8	2
73	Autotransplantation of ovarian tissue and the risk of disease transmission. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2004 , 113 Suppl 1, S48-9	2.4	7
72	Pseudoautosomal linkage of familial Hodgkin's lymphoma: molecular analysis of a unique family with Leri-Weill dyschondrosteosis and Hodgkins lymphoma. <i>British Journal of Haematology</i> , 2003 , 121, 377-9	4.5	5
71	Imatinib mesylate (STI-571 Glivec [®] , Gleevec [®]) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. <i>European Journal of Cancer</i> , 2003 , 39, 2006-2011	7.5	339
70	Restoration of fertility after treatment for cancer. <i>Hormone Research in Paediatrics</i> , 2003 , 59 Suppl 1, 21-3	3.3	44
69	The value of bone marrow examination in the staging of Hodgkin's lymphoma: a review of 955 cases seen in a regional cancer centre. <i>British Journal of Haematology</i> , 2002 , 119, 408-11	4.5	71
68	Semen cryopreservation, utilisation and reproductive outcome in men treated for Hodgkin's disease. <i>British Journal of Cancer</i> , 2002 , 87, 381-4	8.7	65
67	ChLVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin's disease. <i>Journal of Clinical Oncology</i> , 2002 , 20, 2988-94	2.2	68
66	Randomized placebo-controlled trial of testosterone replacement in men with mild Leydig cell insufficiency following cytotoxic chemotherapy. <i>Clinical Endocrinology</i> , 2001 , 55, 315-24	3.4	87
65	A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma. <i>British Journal of Cancer</i> , 2001 , 84, 465-9	8.7	49
64	Ovarian tissue harvested from lymphoma patients to preserve fertility may be safe for autotransplantation. <i>Human Reproduction</i> , 2001 , 16, 2056-60	5.7	177

63	A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma. <i>British Journal of Cancer</i> , 2001 , 85, 29-35	8.7	39
62	Isolation of germ cells from human testicular tissue for low temperature storage and autotransplantation. <i>Fertility and Sterility</i> , 2001 , 75, 269-74	4.8	174
61	Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. <i>European Journal of Cancer</i> , 2001 , 37, 870-7	7.5	293
60	Orthotopic reimplantation of cryopreserved ovarian cortical strips after high-dose chemotherapy for Hodgkin's lymphoma. <i>Lancet, The</i> , 2001 , 357, 1172-5	40	303
59	Autotransplantation of ovarian tissue. <i>Lancet, The</i> , 2001 , 358, 588	40	3
58	Autotransplantation of ovarian tissue. <i>Lancet, The</i> , 2001 , 358, 588	40	
57	Semen collection from young cancer patients. <i>Human Fertility</i> , 2001 , 4, 131-4	1.9	7
56	Achieving pregnancy against the odds: successful implantation of frozen-thawed embryos generated by ICSI using spermatozoa banked prior to chemo/radiotherapy for Hodgkin's disease and acute leukaemia. <i>Human Reproduction</i> , 2001 , 16, 107-109	5.7	20
55	Patterns of relapse and subsequent management following high-dose chemotherapy with autologous haematopoietic support in relapsed or refractory Hodgkin's lymphoma: a two centre study. <i>Annals of Oncology</i> , 2000 , 11, 715-9	10.3	23
54	The impact of mild Leydig cell dysfunction following cytotoxic chemotherapy on bone mineral density (BMD) and body composition. <i>Clinical Endocrinology</i> , 2000 , 52, 609-16	3.4	37
53	A doxorubicin-based regimen used in the treatment of elderly patients with high-grade non-Hodgkin's lymphoma. <i>Clinical Oncology</i> , 2000 , 12, 153-7	2.8	1
52	A phase II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone (FMD) in patients with follicular lymphoma. <i>Annals of Oncology</i> , 2000 , 11, 861-5	10.3	31
51	European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. <i>Journal of Clinical Oncology</i> , 2000 , 18, 317-24	2.2	404
50	Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. <i>Journal of Clinical Oncology</i> , 2000 , 18, 1316-23	2.2	301
49	Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. <i>European Journal of Cancer</i> , 2000 , 36, 61-7	7.5	108
48	Fatigue, sexual function and mood following treatment for haematological malignancy: the impact of mild Leydig cell dysfunction. <i>British Journal of Cancer</i> , 2000 , 82, 789-93	8.7	73
47	. <i>Annals of Oncology</i> , 2000 , 11, 173-174	10.3	3
46	International Consensus Conference on high-dose therapy with hematopoietic stem-cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury. <i>Annals of Oncology</i> , 1999 , 10, 13-9	10.3	21

45	Assessment and significance of mediastinal bulk in Hodgkin's disease: comparison between computed tomography and chest radiography. <i>Journal of Clinical Oncology</i> , 1999 , 17, 2493-8	2.2	35
44	International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury. <i>Journal of Clinical Oncology</i> , 1999 , 17, 423-9	2.2	220
43	Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenström's macroglobulinemia, and mantle-cell lymphoma. <i>Journal of Clinical Oncology</i> , 1999 , 17, 546-53	2.2	149
42	An audit of primary surgical treatment for women with ovarian cancer referred to a cancer centre. <i>British Journal of Cancer</i> , 1999 , 80, 444-7	8.7	15
41	Further investigation of the role of HLA-DPB1 in adult Hodgkin's disease (HD) suggests an influence on susceptibility to different HD subtypes. <i>British Journal of Cancer</i> , 1999 , 80, 1405-11	8.7	32
40	Treatment outcome and prognostic factors for relapse after high-dose chemotherapy and peripheral blood stem cell rescue for patients with poor risk high grade non-Hodgkin's lymphoma. <i>Bone Marrow Transplantation</i> , 1999 , 24, 271-7	4.4	17
39	Testicular function after cytotoxic chemotherapy: evidence of Leydig cell insufficiency. <i>Journal of Clinical Oncology</i> , 1999 , 17, 1493-8	2.2	126
38	Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: clinical benefits at no extra cost. <i>British Journal of Cancer</i> , 1998 , 77, 1294-9	8.7	49
37	Randomized comparison of progenitor-cell mobilization using chemotherapy, stem-cell factor, and filgrastim or chemotherapy plus filgrastim alone in patients with ovarian cancer. <i>Journal of Clinical Oncology</i> , 1998 , 16, 2601-12	2.2	34
36	The role of computed tomography in the management of ovarian tumours of borderline malignancy. <i>Clinical Radiology</i> , 1997 , 52, 280-3	2.9	6
35	Prognostic factors for disease progression in advanced Hodgkin's disease: an analysis of patients aged under 60 years showing no progression in the first 6 months after starting primary chemotherapy. <i>British Journal of Cancer</i> , 1997 , 75, 110-5	8.7	22
34	Follow up policy after treatment for Hodgkin's disease: too many clinic visits and routine tests? A review of hospital records. <i>BMJ: British Medical Journal</i> , 1997 , 314, 343-6		83
33	A randomised trial investigating the dose intensity of primary chemotherapy in patients with ovarian carcinoma: a comparison of chemotherapy given every four weeks with the same chemotherapy given at three week intervals. <i>Annals of Oncology</i> , 1996 , 7, 705-11	10.3	17
32	2-chlorodeoxyadenosine (2-CDA) therapy in previously untreated patients with follicular stage III-IV non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , 1996 , 7, 793-9	10.3	17
31	Survival benefit from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , 1996 , 14, 586-92	2.2	80
30	Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 1995 , 13, 1623-31	2.2	63
29	Results of a randomized trial comparing MVPP chemotherapy with a hybrid regimen, ChIVPP/EVA, in the initial treatment of Hodgkin's disease. <i>Journal of Clinical Oncology</i> , 1995 , 13, 2379-85	2.2	42
28	Case report: enlargement of a mediastinal mass during treatment for Hodgkin's disease may be due to accumulation of fluid within thymic cysts. <i>Clinical Radiology</i> , 1995 , 50, 61-2	2.9	2

27	Gonadal function following chemotherapy for Hodgkin's disease: a comparative study of MVPP and a seven-drug hybrid regimen. <i>Journal of Clinical Oncology</i> , 1995 , 13, 134-9	2.2	113
26	Metastatic carcinoma of uncertain primary site: a retrospective review of 57 patients treated with vincristine, doxorubicin, cyclophosphamide (VAC) or VAC alternating with cisplatin and etoposide (VAC/PE). <i>Cancer</i> , 1994 , 73, 470-5	6.4	12
25	Weekly VAPEC-B chemotherapy for high grade non-Hodgkin's lymphoma: results of treatment in 184 patients. <i>Annals of Oncology</i> , 1994 , 5, 147-51	10.3	16
24	Male fertility after VAPEC-B chemotherapy for Hodgkin's disease and non-Hodgkin's lymphoma. <i>British Journal of Cancer</i> , 1994 , 69, 379-81	8.7	36
23	Urinary-derived monocyte-colony stimulating factor (P-100) following treatment with carboplatin and etoposide in small cell lung cancer (SCLC). <i>Annals of Oncology</i> , 1993 , 4, 877-81	10.3	2
22	Growth Factors and the Microenvironment 1993 , 36-43		
21	The management of Hodgkin's disease. <i>Annals of Oncology</i> , 1993 , 4, 417-21	10.3	
20	A randomised study of bolus vs continuous pump infusion of ifosfamide and doxorubicin with oral etoposide for small cell lung cancer. <i>British Journal of Cancer</i> , 1993 , 67, 1385-90	8.7	24
19	Predicting septic complications of chemotherapy: an analysis of 382 patients treated for small cell lung cancer without dose reduction after major sepsis. <i>European Journal of Cancer</i> , 1992 , 29A, 81-6	7.5	40
18	Chemotherapy for Hodgkin's disease and aggressive non-Hodgkin's lymphoma. More is better, or is it?. <i>Drugs</i> , 1992 , 44, 1-8	12.1	16
17	Infection risk in patients with small cell lung cancer receiving intensive chemotherapy and recombinant human granulocyte-macrophage colony-stimulating factor. <i>European Journal of Cancer</i> , 1992 , 28, 105-12	7.5	13
16	Suitability of cisplatin solutions for 14-day continuous infusion by ambulatory pump. <i>Cancer Chemotherapy and Pharmacology</i> , 1992 , 29, 252-5	3.5	7
15	An analysis of prognostic factors in stage III and IV Hodgkin's disease treated at a single centre with MVPP. <i>Annals of Oncology</i> , 1991 , 2, 423-9	10.3	11
14	Treatment of relapsed Hodgkin's disease using a weekly chemotherapy of short duration: results of a pilot study in 20 patients. <i>Annals of Oncology</i> , 1991 , 2, 505-9	10.3	10
13	A randomised study of intravenous bolus versus continuous infusion of ifosfamide and doxorubicin with oral etoposide for small-cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 1991 , 117 Suppl 4, S139-40	4.9	5
12	The stability of ifosfamide in aqueous solution and its suitability for continuous 7-day infusion by ambulatory pump. <i>Journal of Cancer Research and Clinical Oncology</i> , 1991 , 117 Suppl 4, S154-6	4.9	12
11	A randomised study of adjuvant MVPP chemotherapy after mantle radiotherapy in pathologically staged IA-IIB Hodgkin's disease: 10-year follow-up. <i>Annals of Oncology</i> , 1991 , 2, 49-54	10.3	20
10	Monocytoid B cell lymphoma. <i>Journal of Clinical Pathology</i> , 1991 , 44, 39-44	3.9	10

9	Intensive therapy for small-cell lung cancer using carboplatin alternating with cisplatin, ifosfamide, etoposide, mid-cycle vincristine, and radiotherapy. <i>Journal of Clinical Oncology</i> , 1991 , 9, 1446-52	2.2	22
8	Granulocyte-macrophage colony stimulating factor (GM-CSF) after high-dose melphalan in patients with advanced colon cancer. <i>British Journal of Cancer</i> , 1990 , 61, 749-54	8.7	41
7	The long-term effects of MVPP chemotherapy for Hodgkin's disease on bone marrow function. <i>British Journal of Cancer</i> , 1990 , 62, 127-32	8.7	16
6	The stability of ifosfamide in aqueous solution and its suitability for continuous 7-day infusion by ambulatory pump. <i>Cancer Chemotherapy and Pharmacology</i> , 1990 , 26, 144-6	3.5	14
5	A comparative study of the nodular and diffuse variants of lymphocyte-predominant Hodgkin's disease. <i>Journal of Clinical Oncology</i> , 1989 , 7, 1303-9	2.2	39
4	Prognostic factors in high and intermediate grade non-Hodgkin's lymphoma. <i>British Journal of Cancer</i> , 1989 , 59, 276-82	8.7	62
3	The significance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin's disease. <i>Journal of Clinical Oncology</i> , 1988 , 6, 940-6	2.2	146
2	Mitomycin C and vinblastine in the treatment of advanced breast cancer. <i>European Journal of Cancer & Clinical Oncology</i> , 1985 , 21, 1475-7		22
1	Urinary 6-oxo prostaglandin F1 alpha in myocardial infarction. <i>British Medical Journal</i> , 1983 , 287, 727		8